At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,184 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, Vehicle, and 2 other interventions for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 1,184 participants.
Detailed Summary
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly (Brinzolamide+Brimonidine) in patients with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartMay 2011
Primary CompletionJan 2013
TodayJul 2026
First PostedMar 7, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.3 years ago
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspensiondrug
Vehicledrug
Inactive ingredients used as a placebo for masking purposes
Brinzolamide 1% ophthalmic suspensiondrug
Brimonidine tartrate 0.2% ophthalmic solutiondrug